And a bit of an update on Replimune's OV. I don't recall seeing this posted, so apologies if it has been already. Makes the Vaxinia results look a lot better....
After Data Miss in Lead Cancer Indication, Replimune Maps Path for Oncolytic Virus - MedCity News.
Replimune’s lead therapeutic candidate did not meet the two main goals of a study intended to support an FDA submission in cutaneous squamous cell carcinoma. But Replimune’s therapy, an oncolytic virus, has better data in melanoma, and the company plans a 2024 FDA submission in this skin cancer.
Link for article: After Data Miss in Lead Cancer Indication, Replimune Maps Path for Oncolytic Virus - MedCity News
Why IMU is a multi multi bagger, page-20504
Add IMU (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
7.1¢ |
Change
0.000(0.00%) |
Mkt cap ! $519.7M | |||
| Open | High | Low | Value | Volume |
| 7.0¢ | 7.4¢ | 7.0¢ | $1.222M | 16.98M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 5 | 942474 | 7.1¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 7.2¢ | 200000 | 2 |
View Market Depth
| Last trade - 16.10pm 14/05/2024 (20 minute delay) ? |
|
|||||
|
Last
7.2¢ |
Change
0.000 ( 1.85 %) |
||||
| Open | High | Low | Volume | ||
| 7.1¢ | 7.3¢ | 7.0¢ | 6985767 | ||
| Last updated 15.59pm 14/05/2024 ? | |||||
| IMU (ASX) Chart |